MONTREAL--(BUSINESS WIRE)--Jubilant DraxImage Inc. announced today it has appointed James Kaufman as Director Marketing, PET Products effective immediately. Reporting, to Michael Rossi, President, Jubilant DraxImage, James will be responsible for leading the development and commercialization of the Cardiovascular PET products. Included in his accountabilities will be the launch and global expansion of RUBY-FILL®.
“We are very pleased to welcome Jim to the Jubilant DraxImage team. With more than 20 years of medical imaging experience, Jim brings to the table a strong proficiency in nuclear medicine knowledge and business development competency,” said Michael Rossi, President, Jubilant DraxImage. “Jim’s expertise, professionalism and business focus are major assets for Jubilant DraxImage.”
Jim joins Jubilant DraxImage from GE Healthcare where he served as the Global Product Leader, Life Sciences-Core Imaging. His main areas of proficiency are founded in direct to physician Marketing and Sales, as well as Business Development and Brand team management. He also brings to JDI extensive Nuclear Medicine and Molecular Imaging knowledge, with a specialisation in Cardiology products as well as Neurology, Oncology and general nuclear imaging segments.
James holds a Bachelor of Science in Business Administration and Marketing from Ashland University, Ashland, Ohio. He received his Nuclear Medicine Technology training at The Ohio State University and is Board Certified in Nuclear Medicine Technology.
About Jubilant DraxImage
Jubilant DraxImage Inc., a wholly Owned Subsidiary of Jubilant Pharma Ltd, which is held by Jubilant Life Sciences Ltd, develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of diseases. The company is dedicated to nuclear medicine and serves customers and through them patients, globally, with high quality and reliable products and services. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer, MAA (lung perfusion imaging), DTPA (renal and brain imaging) and MDP (bone imaging), and also markets other products such as Sestamibi, Xenon and Gluceptate. The company has a strong development pipeline of new products and commitment in bringing new products to market. For more info: www.draximage.com
About Jubilant Life Sciences
Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Ltd, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products through 6 USFDA approved facilities in India, US and Canada. The Life Science Ingredients segment is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment provides proprietary in-house innovation and collaborative research and partnership for out-licensing through 3 world class research centres in India and US. Jubilant Life Sciences Ltd has a team of around 6,500 multicultural people across the globe and is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.
Back to HCB News
